Methylprednisolone Pulses Plus Tacrolimus in Addition to Standard of Care vs. Standard of Care Alone in Patients With Severe COVID-19. A Randomized Controlled Trial

Frontiers in Medicine

Raúl Rigo-Bonnin¹  Santiago Bolivar²  Nahum Calvo²  Anna Mensa-Vilaró³  Arnau Antolí⁴  Xavier Solanich⁴  Adriana Iriarte⁴  Gemma Rocamora-Blanch⁴  Marta Fanlo-Maresma⁴  Francesca Mitjavila⁵  Olga Capdevila⁵  Antoni Riera-Mestre⁵  Xavier Corbella⁶  Jordi Niubó⁷  Núria Padullés⁸  Vanesa Vicens-Zygmunt⁹  Cristian Tebe^1,10  Sebastià Videla^1,11  Pilar Hereu^1,11  Jordi Bas^1,12  Laura Arregui^1,13 

[1] Department of Clinical Laboratory, Hospital Universitari de Bellvitge, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain;Department of Diagnostic Imaging, Hospital Universitari de Bellvitge, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain;Department of Immunology, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain;Department of Internal Medicine, Hospital Universitari de Bellvitge, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain;Department of Internal Medicine, Hospital Universitari de Bellvitge, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain;Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain;Department of Internal Medicine, Hospital Universitari de Bellvitge, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain;School of Medicine, Universitat Internacional de Catalunya, Barcelona, Spain;Department of Microbiology, Hospital Universitari de Bellvitge, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain;Department of Pharmacy, Hospital Universitari de Bellvitge, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain;Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain;Department of Pneumology, Hospital Universitari de Bellvitge, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain;Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain;Department of Biostatistics, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain;Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain;Department of Clinical Pharmacology, Hospital Universitari de Bellvitge, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain;Clinical Research and Clinical Trial Unit (UICEC-IDIBELL), Spanish Clinical Research Network, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain;Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain;Department of Immunology, Hospital Universitari de Bellvitge, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain;HUB-ICO-IDIBELL Biobank, Spanish Clinical Research Network, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain;

关键词: COVID-19;    SARS-CoV-2;    methylprednisolone;    tacrolimus;    inflammation;    lung injury;   

DOI  :  10.3389/fmed.2021.691712

来源: Frontiers

【 授权许可】

CC BY